Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Observational × pembrolizumab × Clear all

Status

Sponsor Class

OTHER 35 INDUSTRY 6 UNKNOWN 1 OTHER_GOV 1 INDIV 1

Study Type

Interventional 15 Observational 1

Sponsor

Conditions

Efficacy, Team 1

Interventions

Surveys and Questionnaires 7 Blood Specimen Collection 7 Observation 5 Surgical Procedures, Operative 4 Radiotherapy 4 Drug Therapy 4 Physical Examination 3 Magnetic Resonance Spectroscopy 3 Endoscopic Mucosal Resection 3 Zoledronic Acid 2 Watchful Waiting 2 Thyroidectomy 2 Radiosurgery 2 Radiation 2 Neoadjuvant Therapy 2 Mass Screening 2 Hematologic Tests 2 Gastrectomy 2 Elective Surgical Procedures 2 Echocardiography 2 Control Groups 2 Blood Transfusion 2 Base Sequence 2 technetium Tc 99m-Sn aggregated albumin 1 regorafenib 1 pembrolizumab 1 osimertinib 1 exemestane 1 enzalutamide 1 entecavir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡